Retinoid X receptor–Peroxisome proliferator-activated receptor gamma heterodimer (RXR–PPARγ heterodimer)

The retinoid X receptor–peroxisome proliferator-activated receptor gamma heterodimer (RXR–PPARγ) is a nuclear receptor complex that forms by the obligate interaction between RXR and PPARγ. Each subunit contains ligand-binding, DNA-binding, and activation domains. Upon binding specific ligands (e.g., thiazolidinediones for PPARγ or 9-cis-retinoic acid for RXR), the complex binds to peroxisome proliferator response elements (PPREs) in DNA and regulates transcription of genes that control glucose and lipid metabolism, adipogenesis, and inflammatory responses. The RXR–PPARγ heterodimer is a validated drug target for metabolic diseases such as type 2 diabetes and non-alcoholic fatty liver disease, as well as for certain cancers and neurodegenerative disorders. Its complex pharmacology allows for selective modulation by different ligands, but can also lead to safety concerns such as weight gain and fluid retention.

Other names

RXR–PPARγ heterodimerRetinoid X receptor alpha–Peroxisome proliferator-activated receptor gamma heterodimer (RXRα–PPARγ)RXR–PPARgammaPPARγ–RXR heterodimer

Ligand-activated gene transcription: Binding of ligands (either to PPARγ or RXR) induces conformational changes in the heterodimer, promoting recruitment of coactivator proteins and activating transcription of downstream genes involved in metabolism. Additive/Cooperative activation: Ligands for either RXR or PPARγ alone can activate the heterodimer, while simultaneous activation produces an additive effect on gene transcription. Selective modulation: Distinct ligands may preferentially recruit different coactivators, modulating the transcriptional output.